Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

The Malvern location of Fujirebio Diagnostics Inc.’s played key role in the clinical development of the first FDA-approved ...

PALO ALTO, CALIFORNIA / ACCESS Newswire / May 28, 2025 / Bioz, Inc., a global leader in AI-powered scientific citation ...

Fujirebio collaborates with Stanford Medicine to advance research and innovation in the field of infectious disease testing: Tokyo, Japan Saturday, June 7, 2025, 13:00 Hrs [IST] F ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...

Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the ...

GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated ...

PALO ALTO, CALIFORNIA / ACCESS Newswire / May 28, 2025 / Bioz, Inc., a global leader in AI-powered scientific citation management, is proud to collaborate with Fujirebio, further strengthening its com ...

The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose ...